Conditions: Chronic hepatitis B. Department of Hepatology, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, Husi Baiheti Patient description and treatment expectations: Description of condition: The patient was found to have positive markers of hepatitis B for more than 20 years and was a patient with HBeAg(-) chronic hepatitis B. He was treated with lamivudine antiviral therapy for 2 years and HBV-DNA did not fall below the lower limit of detection. Treatment expectation: HBV-DNA below the lower limit of detection, HBsAg disappeared Examination and medication: Diagnosis: HBeAg(-) chronic hepatitis B Laboratory findings at the time of consultation: Liver function: normal, Hepatitis B markers: HBsAg(+), HBeAg(-), HBeAb(+), HBcAb(+), HBsAg 175.10, HBV DNA. 1.25E+003copies/ml Treatment course: The patient was treated with Pyroxin for 4 weeks and HBV-DNA was observed: below the lower limit of detection. After 12 weeks of treatment with Pyroxin, observe the decline in HBsAg quantification from 175.10IU/ml to 8.31IU/ml, and HBsAb quantification also rose slowly to 2.22IU/ml. after treatment to 20 weeks, HBsAg quantification 5.69IU/ml and HBsAb quantification 3.03IU/ml, add Anzai time (times/two weeks), hoping to stimulate Autoimmunity to raise HBsAb level, treatment to 36 weeks, HBsAg quantification <0.05IU/ml, HBsAb quantification 37.42IU/ml, discontinued Pyroxin, hepatitis B vaccine + immunoglobulin (times/month), aiming to raise HBsAb level to more than 100IU/ml, treatment to 52 weeks, HBsAg quantification <0.05IU/ml, HBsAb quantification 263.50 IU/ml, end of treatment. Expert summary: Reasons for treatment plan and medication selection: The patient was relatively young, and because he had used lamivudine for 2 years, the effect was not obvious, and the patient was eager for a better treatment effect. The patient's HBsAg quantification was extremely low and her compliance was good, so she chose Pyroxin treatment in the hope of achieving lasting immune control and even the disappearance of HBsAg. Treatment course and follow-up results: The treatment course was preset to 12 weeks, and the decrease in HBsAg quantification was observed; if the decrease was obvious, the treatment was continued; if the decrease was not obvious, Pyroxin was discontinued and oral antiviral drug treatment was continued. After 36 weeks of treatment, HBsAb was 37.42 IU/ml, Pyroxin was discontinued and hepatitis B vaccine + immunoglobulin was added with the aim of raising HBsAb level to more than 100 IU/ml, and treatment was completed at 52 weeks with HBsAb quantification of 263.50 IU/ml. The patient's current condition is stable, HBsAb quantification is maintained above 100IU/ml, and the healing process is good. Adverse reaction management experience: the patient had less adverse reactions and better compliance during treatment - durable immune control is the key to chronic hepatitis B treatment. Interferon has a dual mechanism of action and is the preferred regimen for the pursuit of durable immune control and even HBsAg clearance. --- HBsAg quantification and decline at 24 weeks of treatment can be used as the basis for treatment regimen adjustment. --- Patient education and concern for adverse effects are also integral to treatment and are important for ultimate treatment success. Appropriate management of pre- and on-treatment adverse reactions can improve patient compliance.